Long-Term Follow-Up of E3311, an ECOG-ACRIN Cancer Research Group Phase II Trial of Transoral Surgery and Risk-Based Adjuvant Treatment in Human Papillomavirus–Initiated Oropharynx Cancer Despite ...

Over 85,000 adolescents and young adults (AYAs; age 15-39 years) are diagnosed with cancer annually in the United States, with nearly 85% expected to become long-term survivors. 1-4 Cancer survivors ...

Artificial intelligence (AI) has the potential to transform HNSCC care by addressing critical challenges in diagnostics, prognostics, and treatment decision making. 5,6 Within AI, machine learning ...

Advancements in early detection and multimodal treatment strategies have significantly improved survival rates for early-stage breast cancer, now exceeding 80% at 10 years. However, breast cancer ...

Women are increasingly becoming a significant force in medicine, with their proportion rising from 26% in 2004 to 38% in 2022. 1 This trend extends across all medical subspecialties, with female ...

Genomic Characterization of Papillary Thyroid Cancer Reveals Germline Mutations Associated With Congenital Hypothyroidism Twenty-five patients were recruited in the study (14 male and 11 female ...

Randomized trial of standard chemotherapy alone or combined with atezolizumab as adjuvant therapy for patients with stage III deficient DNA mismatch repair (dMMR) colon cancer (Alliance A021502; ...

Anlotinib versus bevacizumab added to standard first-line chemotherapy among patients with RAS/BRAF wild-type, unresectable metastatic colorectal cancer: A multicenter, prospective, randomised, phase ...

Receipt of chemotherapy at the end of life (EOL) has been associated with outcomes signaling poor-quality EOL care, such as death in a hospital, high health services use at the EOL, and a shorter ...

Background: The standard STUPP regimen (radiotherapy with temozolomide [TMZ] followed by adjuvant TMZ) remains limited in efficacy for newly diagnosed glioblastoma (GBM). Anlotinib, a multi-kinase ...

Event-free survival (EFS) in MATTERHORN: A randomized, phase 3 study of durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel chemotherapy (FLOT) in resectable gastric/gastroesophageal ...

Background: Both Becotatug (JMT101, humanized IgG1 anti-EGFR monoclonal antibody [mAb]) ± chemotherapy, and Enlonstobart (SG001, humanized IgG4 anti-PD-1 mAb), demonstrated promising antitumor ...